Volume Alert - VRX 136.16 Valeant Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 11:28 AM

Volume Alert - VRX 136.16 Valeant Pharmaceuticals International $VRX Hit a high today of 136.50 Closing the day 10:30 at 136.16 +1.95 +1.45% With a day low of 132.73 and a total volume of 3,820,934.

VRX Recent Posts: http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/

VRX Valeant Pharmaceuticals International Recent Headline News

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - 28 mins ago
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.91 (+0.77), AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.52 (+4.75)

Actavis to spend $66B on Allergan
By TOM MURPHY - AP - 40 mins ago
Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.
DRTX: 23.94 (+0.19), AGN: 210.73 (+12.08), ACT: 248.52 (+4.75), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - 1 hr 10 mins ago
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.45 (+4.68)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - 1 hr 13 mins ago

ACT: 248.45 (+4.68), VRX: 135.65 (+1.44)

Valeant Comments On Allergan Announcement
PR Newswire - 1 hr 58 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)

Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - 2 hrs 15 mins ago
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 210.77 (+12.12), HAS: 56.31 (+2.29), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HAL: 50.68 (-4.40), DIS: 90.31 (-0.49), DWA: 22.28 (-3.74), BHI: 66.73 (+6.84)

Today's Market: Pharma And Tech Companies In Focus This Morning
Matthew Smith - at Seeking Alpha - 2 hrs 20 mins ago

AGN: 210.77 (+12.12), VRX: 135.65 (+1.44), ACT: 248.63 (+4.86), LNKD: 222.45 (-11.44), FB: 74.13 (-0.75), MSFT: 49.26 (-0.32), GOOG: 534.89 (-9.51)

Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 27 mins ago
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 23.94 (+0.19), ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44)

Tracking Bill Ackman's Pershing Square Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 6:40AM CST

ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), HLF: 38.48 (-0.02), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HHC: 142.97 (-0.71), PAH: 25.70 (+0.20), CP: 204.86 (+0.30), APD: 134.99 (+0.28), BKW: 32.05 (-0.24)

Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), F: 15.35 (+0.21), FB: 74.13 (-0.75), PFE: 29.95 (-0.39), AGN: 210.79 (+12.14), YHOO: 51.35 (-0.40), PBR: 9.61 (-0.34), DFS: 64.86 (-0.12), DTSI: 32.78 (-0.25), SPY: 203.88 (-0.36), LNKD: 222.45 (-11.44), QQQ: 102.51 (-0.71), AME: 51.12 (-0.58), MRK: 59.71 (+0.64), AOL: 46.28 (+0.24), AZN: 72.14 (-0.71), GM: 32.16 (+0.37), CVEO: 10.53 (-0.11), DD: 70.50 (-0.30)

Actavis near deal to acquire Allergan for $210-220/share
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 2:51PM CST

AGN: 210.79 (+12.14), ACT: 248.64 (+4.87), VRX: 135.65 (+1.44)

Tracking Lou Simpson's SQ Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sun Nov 16, 10:03AM CST

BAM: 49.79 (+0.18), VRX: 135.65 (+1.44), LBTYK: 45.43 (-0.57), CCK: 48.22 (+0.68), WFC: 53.21 (-0.14), ORCL: 40.93 (+0.09), UPS: 106.40 (-0.43), MCO: 100.43 (-0.04), T: 35.84 (-0.06), USB: 43.75 (+0.02), TEL: 60.90 (-0.63), DTV: 87.22 (-0.33), BRK.B: 145.40 (-0.12), BRK.A: 218,035.00 (+12.00), SCHW: 28.57 (-0.30)

Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sat Nov 15, 10:45AM CST

KMI: 39.78 (+0.41), VRX: 135.65 (+1.44), HAL: 50.69 (-4.39), KMP: 97.14 (+0.89), BAC: 17.11 (-0.03), TDW: 37.56 (-0.23), VPRT: 67.60 (+0.80), ORCL: 40.93 (+0.09), PRI: 51.71 (-0.34), EPB: 41.87 (+0.42), ESRX: 78.35 (+0.48), EQIX: 221.58 (-0.51), JPM: 60.28 (unch), KMR: 98.09 (+1.13), MSFT: 49.26 (-0.32), CMCSA: 54.12 (+0.02), SCHW: 28.57 (-0.30)

After Yesterday's Rally of 1.80% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Nov 14, 3:59PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $131.34 to a high of $134.64. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $133.84 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 135.65 (+1.44)

Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:20PM CST
Merck KGaA (MKGAF) reported third-quarter 2014 earnings of $1.53 per American Depositary Receipt (ADR), up 0.2% from the year-ago quarter.
LCI: 47.36 (+0.48), VRX: 135.65 (+1.44), ADHD: 3.45 (-0.21)

Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST

ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), VRX: 135.65 (+1.44), ACT: 248.67 (+4.90)

Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), ACT: 248.67 (+4.90), VRX: 135.65 (+1.44)

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

University of Phoenix Unveils Credit for Prior Learning Advantages

Navigating College Credits with Life Experience If you think school is the only place to pick up education that counts, think again. University of Phoenix is challenging this by recognizing the value of the hustle and grind working adults go through. During the recently wrapped-up National Transfer Student Week, Devin Andrews, their VP of Admissions and Evaluation, shed...

Estrogen Patch Struggles: Menopause Care Needs a Boost

Troublesome Estrogen Patch Shortages Hit Hard You'd think getting a prescription filled would be a simple task, right? Well, think again. Midi Health shines a glaring light on how the supposed ease of getting hormone therapy is anything but for many women in 2026. Out of those scrambling for estradiol patches, 44% hit roadblocks in pharmacies, and a third hit an all-out...

Advocacy for Hiring Disabled Kidney Patients Gains Steam

Making Jobs Accessible for Kidney Patients Well, things are stirring up on Capitol Hill, and it's high time, if you ask me. The American Association of Kidney Patients (AAKP) is rallying hard for a bipartisan bill that could change the landscape for folks grappling with kidney diseases and disabilities. You’ve got Reps Pete Sessions and Steny Hoyer pushing this American...

Salus Scientific Pioneers Safety at TCT 2026

Revolutionizing Occupational Safety in Healthcare Radiation exposure in the medical field: the dull, ominous toll it takes on healthcare professionals, often cloaked in acceptance as a mere occupational hazard. But here's Salus Scientific crashing into the party at TCT 2026 like a seasoned rockstar, demanding we stop accepting the dangers of fluoroscopy-guided procedures...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Miraculous Medical Team Effort Saves Newborn's Life

A Medical Feat: Teamwork at Its Pinnacle You want a story that restores your faith in humanity? Well, this one from Memorial Healthcare System and Joe DiMaggio Children's Hospital might just do the trick. The tale of baby Jay'ce, born with a neck mass threatening his breath, is straight out of a medical drama—albeit without the Hollywood scriptwriters' spin. It’s rare...

Biotech's Future Faces Tight Investment Restrictions

Biotech Investment: Between a Rock and a Hard Place The U.S. Department of the Treasury just threw a curveball at the biotechnology sector with its proposal to shore up the Comprehensive Outbound Investment National Security (COINS) Act. This ain't just another set of lines on a folded napkin; the new rules would put a chokehold on American investments flowing into...

Beyond The Bounce Expands with Pro Pickleball Star

Pickleball's Power Play: The Media Move Out of the blue, the world of niche sports finds its hub. Beyond The Bounce steps up to the plate by roping in pickleball’s own Zane Navratil. The hype’s not in the spin here—this is serious business. The company plans to push the boundaries of the sport into mainstream media, or at least give it a decent shot. Zane Navratil:...

FP Movement Opens Energizing Boutique in Cranston, RI

FP Movement Expands with Style in Rhode Island FP Movement is shaking things up in Cranston, Rhode Island, bringing its signature activewear vibe to Garden City Center with a new shop. It’s not just about buying leggings anymore; it’s about diving into a lifestyle that screams energy and community spirit. The store, which spans 1,209 selling-square-feet, opened its...